
Opinion|Videos|January 22, 2025
Safety Profile of Second-Line Agent in Patients With Compensated Cirrhosis
Panelists discuss how the safety profiles of second-line primary biliary cholangitis (PBC) therapies in compensated cirrhosis show varying levels of risk, with recent abstracts from EASL and AASLD 2024.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do the safety profiles of seladelpar, elafibranor, and obeticholic acid impact their use in patients with compensated cirrhosis?
- Include in your discussion the EASL 2024 abstract.
- Include in your discussion the EASL 2024 abstract.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
COVID-19 mRNA Vaccines May Boost Immunotherapy Response in Cancer
2
KEYNOTE Trial Data Presented at ESMO 2025 Congress Reiterate Pembrolizumab’s Benefits in NSCLC
3
States Push Forward on Insurance Mandates for GLP-1 and Obesity Treatments
4
Court Ruling Highlights Risks of Improper Dose Adjustments
5














































































































































































































